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Abstract
Background: Inhibition of Akt signaling is considered one of the most promising therapeutic strategies for many cancers.
However, rational target-orientated approaches to cell based drug screens for anti-cancer agents have historically been
compromised by the notorious absence of suitable control cells.
Methodology/Principal Findings: In order to address this fundamental problem, we have developed BaFiso, a live-cell
screening platform to identify specific inhibitors of this pathway. BaFiso relies on the co-culture of isogenic cell lines that
have been engineered to sustain interleukin-3 independent survival of the parental Ba/F3 cells, and that are individually
tagged with different fluorescent proteins. Whilst in the first of these two lines cell survival in the absence of IL-3 is
dependent on the expression of activated Akt, the cells expressing constitutively-activated Stat5 signaling display IL-3
independent growth and survival in an Akt-independent manner. Small molecules can then be screened in these lines to
identify inhibitors that rescue IL-3 dependence.
Conclusions/Significance: BaFiso measures differential cell survival using multiparametric live cell imaging and permits
selective inhibitors of Akt signaling to be identified. BaFiso is a platform technology suitable for the identification of small
molecule inhibitors of IL-3 mediated survival signaling.
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Introduction
Cell-based screens have been widely used in drug discovery
although historically, these assays are conducted using genetically
diverse cell lines derived from human tumors [1,2]. Since the
complex intracellular signaling networks that drive cancer cell
growth and survival have begun to be elucidated, a more rational
approach to drug discovery has become feasible [3]. However, the
implementation of target-orientated cell-based screens for anti-
cancer drugs remains a challenge, both because of their reliance on
defined genetic changes and because of the lack of proper control
cells. To overcome this fundamental problem, we have developed a
rational strategy for cell-based drug discovery that is based on the
convenience and flexibility of the Ba/F3 cell system, an immortalized
IL-3-dependent pro-B lymphoblastic cell line [4]. IL-3 supports the
growth and survival of Ba/F3 cells through the activation of distinct
signaling pathways. Upon binding to its cognate receptor IL-3
activates the Janus kinase signal transduction and transcriptional
activation pathways (JAK/STAT) to induce Bcl-xL [5]. Similarly,
IL-3 activation of the PI3K/Akt pathway is involved in inhibiting the
intrinsic apoptotic machinery in Ba/F3 cells [6–8].
Overexpression of several constitutively active signaling mole-
cules abrogates the dependence of these cells on IL-3 [9]. Hence,
we generated isogenic cell lines derived from Ba/F3 (BaFiso) in
which IL-3 independent survival is sustained by independent
signaling events. Each of these isogenic lines was genetically
labeled with a fluorescent reporter and thus, the ratio of two
spectrally distinct cell populations could be used as primary
endpoint of the system to monitor pathway-specific cytotoxicity.
Accordingly compounds can be screened in co-cultures of these
lines and the change in the relative cell number of the two lines
readily and rapidly measured to identify those molecules that
specifically interact with one of the signaling pathways. In this
instance, BaFiso has been designed as a live-cell system suitable to
identify specific inhibitors of Akt signaling.
Results
Tagging isogenic Ba/F3 cells individually with two
different chromophores
The BaFiso system is a dual fluorescence cell-based screening
system in which compounds can be readily monitored thanks to
the stable expression of yellow or cyan fluorescent proteins that
individually tag each of the isogenic cell lines (Fig. 1). To introduce
the genes encoding the different fluorescent proteins into Ba/F3
cells, retroviral supernatants were generated by transfection of
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LinX packaging cells. Through clonal propagation, we were able
to establish Ba/F3 cell lines that robustly and homogeneously
expressed ECFP (Fig. 2A and B) or EYFP (Fig. 2C and D). Stable
transfectants of these proteins were FACS-sorted to ensure that
they expressed similar levels of the fluorescent reporter protein.
Generation of double stable Ba/F3 cell lines
The strategy described here is based on paired isogenic cell lines
whose survival in the absence of IL-3 is sustained by the activation
of independent signaling pathways. Several signaling pathways
have been implicated in IL-3-mediated survival, including those
involving Akt and Stat5 [10,11]. In order to introduce constitu-
tively active forms of these genes into our dual fluorescence cell-
based system, we used retroviral constructs carrying a myristoy-
lated derivate of Akt and STAT5A1*6, which contains two
activating amino acid substitutions [11]. The yellow labeled Ba/F3
cells were used to generate Akt-dependent reporter cells whereas
the cyan tagged cells were used to establish PI3K/Akt independent
reporter cells. The retroviral supernatants of LinX packaging cells
were employed to transduce Ba/F3/EYFP cells (BY) with myr-Akt
and Ba/F3/ECFP cells (BC) with STAT5A1*6 (Fig. 2E). Stably
expressing cell clones were selected and the expression of the
transgenes was confirmed by western blot analysis (Fig. 2F). The
level of Akt expression was monitored using an antibody that
recognizes Akt irrespective of its phosphorylation state. Akt
migrates as a single band with an apparent molecular weight of
60 kDa, although a larger protein was also identified in
immunoblots of Akt from lysates of BYA cells. This additional
form can be explained by the difference in size produced by the
myristoylation signal present in the constitutive active form of Akt
used to generate the BYA cell line. Despite the Stat5a protein
present in the parental BC cells, ectopic expression of the
constitutively active form of Stat5a in BCS cells could be
unequivocally demonstrated in western blots probed with an
antibody directed against the Flag-tag. Indeed, STAT5A1*6
expression also increased the total Stat5a protein level in BCS
cells as shown by immunoblotting using an antibody recognizing
Stat5.
Figure 1. Schematic overview of the BaFiso assay system. BaFiso consists of paired isogenic cell lines that have been engineered to acquire IL-
3 autonomous growth through constitutive activation of Akt or Stat5 signaling. The two cell lines to be compared are individually tagged with either
yellow or cyan fluorescent proteins. Equal numbers of yellow and cyan cells were co-cultured, treated with compounds and the change in the relative
cell number was calculated on the basis of the distinct fluorescent proteins measured. Our strategy aims to identify lead compounds that specifically
kill test cells with activated Akt signaling (yellow cells) and that spare the otherwise isogenic control cells (cyan cells).
doi:10.1371/journal.pone.0001823.g001
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To examine whether PI3K/Akt or Stat5 signaling is indeed
activated in the stable BYA or BCS cells respectively, we analyzed
downstream elements in these two pathways. Phosphorylation of
Akt (Ser473) has been widely used as a read out of activation of the
PI3K pathway. When we compared the level of Akt phosphor-
ylation in lysates of BY and BYA cells cultured in the presence of
IL-3, there was dramatic increase in Ser473 phosphorylation of
Akt in BYA cells, reflecting the activity of this pathway. To
investigate whether the activation of Akt in BYA cells had an
impact on downstream events, we analyzed the Thr389 phos-
phorylation of the linker domain of the p70 S6 kinase that is
constitutively activated upon overexpression of a gag fusion of Akt
[12]. There was a significant increase in the intensity of the band
corresponding to p70 S6 kinase (Thr389) in BYA cells when
compared to BY control cells. On the other hand, the expression
of the known STAT5 target gene, pim-1, was upregulated upon
expression of constitutive activated Stat5a, consistent with previous
studies [13].
Ectopic expression of activated Akt and Stat5a confers IL-
3 independence
Consistent with previous reports, expression of constitutively
active mutants of Akt and Stat5a provide signals for cytokine-
independent survival of Ba/F3 cells [9,11]. The increased
resistance to IL-3 withdrawal of the BYA and BCS cell lines
when compared to the parental BY and BC cell lines was
Figure 2. The generation of BaFiso cell lines. Ba/F3 cells were transduced with retroviral supernatant carrying pBabePuro-EYFP or pBabePuro-
ECFP. Cell clones were established and sorted in a fluorescence activated cell sorter (FACS) to generate lines homogeneously expressing the
corresponding fluorescent tags. (A) and (C), viable Ba/F3 cells show robust and homogeneous expression of the respective fluorescent protein. (B)
and (D), corresponding light field views. (E), Generation of stable BaFiso cell lines. Clonal Ba/F3 cells stably expressing EYFP (BY) or ECFP (BC) were
used to generate stable BaFiso cell lines that co-express yellow fluorescence and myr-Akt (BYA), or cyan fluorescence and STAT5A1*6 (BCS). Cell
clones were established and analyzed. (F), Analysis of transgene expression and downstream activation of the corresponding signaling pathways by
western blotting. Antibodies against total Akt, Stat5a, Flag phospho-Akt (Ser473), phospho-p70 S6 (Thr389) and Pim-1 were used and the signals
normalized to the respective a-tubulin levels.
doi:10.1371/journal.pone.0001823.g002
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confirmed by morphological assessment. Parental BY and BC cells
were cultured in the presence or absence of IL-3 and the degree of
cell death was assessed after 24 hours by microscopic examination
(Fig. 3A). The number of cells with an apoptotic phenotype
increased significantly after IL-3 withdrawal in the cultures. The
effect of the constitutive activation of Akt or Stat5 signaling was
examined when IL-3 was withdrawn from representative BYA and
BCS cell clones. As such, the capacity of the constitutively active
forms of the signaling molecules Akt and Stat5a to impede
apoptosis was evident and accordingly, cell death was dramatically
reduced in Ba/F3 cells ectopically expressing myr-Akt or
STAT5A1*6, even in the absence of IL-3 (Fig. 3A). We also
determined the metabolic activity as a measure of cell viability
using the alamar blue assay, in which a redox indicator changes
color from blue to pink depending on metabolic status of the cells
(Fig. 3B). The activity of myr-Akt in BYA cells was significantly
higher in the absence of IL-3 than that of the parental cells.
Similarly, STAT5A1*6 also maintained the activity of BCS cells
albeit to slightly lesser degree (Fig. 3C). We examined the time
course of cell viability following IL-3 withdrawal (Fig. 3D) and
24 hours after IL-3 deprivation, approximately 60% of the BYA
or BCS cells remained viable compared to approximately 25% of
the parental BY and BC cell lines. The viability of BY and BC cells
further diminished after 60 hours of IL-3 starvation to 13% and
9%, respectively. In contrast, the viability of BYA and BCS cells
remained around 50% after 60 hours in the absence of IL-3.
Figure 3. The viability of BaFiso cell lines in the absence of IL-3. (A) Parental Ba/F3 derived BY and BC cells, and the BaFiso cell lines BYA and
BCS were maintained in the presence or absence of IL-3 (+IL3 and2IL3). Photos were taken 24 h after transferring the cells to medium without IL-3 or
in the presence of 3 ng/ml of the recombinant cytokine. (B) Measurement of cell viability using the Alamar blue assay. Alamar blue fluoresces and
changes color in response to chemical reduction, and the extent of the conversion is a reflection of cell viability. Metabolic conversion of Alamar blue
to its reduced, pink derivative upon cytokine-deprivation (2IL-3) or in its presence (+IL-3). (C), Bar graph showing the results of Alamar Blue cell
viability assay. Maximal absorbance of the reduced and oxidized forms of AlamarBlueTM, 570 and 600 nm was measured using Victor 1420 multilabel
counter 24 h after IL-3 withdrawal. The percentage of cell survival was calculated compared with control cells in the presence of 3 ng/ml of IL3. The
data represents three independent experiments performed in triplicate samples. (D) Time course of cell viability upon IL-3 withdrawal. Cells were
washed twice in PBS and seeded in media lacking IL-3. Viability was assessed at 12 hour intervals by trypan blue exclusions followed by cell
countings. Black rhombs and open squares represent percentage viability of BY and BC cells, respectively. Open triangles and black circles represent
percentage viability of BYA and BCS cells, respectively. Data are presented as mean6SD from three independent experiments.
doi:10.1371/journal.pone.0001823.g003
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The protection from IL-3 withdrawal afforded by
enhanced Stat5 signaling is independent of Akt activity
The capacity to monitor pathway-specific cytotoxicity in our
assay is based on the use of isogenic control cells that confer
survival in the absence of IL-3 in an Akt-independent manner.
Since Akt is one of the major downstream targets of PI3K
signaling, its phosphorylation status is commonly used to monitor
the activity of the PI3K/Akt pathway. We analyzed the impact of
ectopic expression of myr-Akt and STAT5A1*6 on Akt activation
using an antibody that specifically recognizes Ser473 phosphor-
ylated Akt (Fig. 4). The intensity of Akt phosphorylation was
compared to the overall expression of Akt and a-tubulin using
specific antibodies. Parental BY and BC cells possess relatively low
basal levels of Akt phosphorylation which further decreased upon
withdrawal of IL-3. Ectopic constitutively active Stat5a expression
had no significant impact on the phosphorylation of Akt in the
presence or absence of IL-3, indicating that the enhanced survival
of BCS cells triggered by STAT5A1*6 upon IL-3 starvation is
independent of Akt signaling. Consistent with previous studies,
overexpression of myr-Akt dramatically augmented Ser473
phosphorylation [14] and high levels of Akt phosphorylation were
still detected in the complete absence of IL-3 (Fig. 4).
In conclusion, these results show that we have generated stable
Ba/F3-derived cell lines in which the inhibition of the intrinsic
apoptotic machinery is mediated by ectopic expression of constitu-
tively active mutants of Akt or Stat5a. Since the abrogation of IL-3
dependence occurred through the activation of independent
signaling pathways, these cell lines can be used together as paired
isogenic test and control cells to identify pathway specific inhibitors.
Detection of selective toxicity associated with activated
Akt signaling
The BaFiso assay was set up in 96-well plates and with an
automated workflow [15]. Equal numbers of BYA and BCS cells
were mixed and seeded at a density of 20,000 cells per well using
multidrop dispenser. All liquid handling for treatment and staining
was carried out by a robotic workstation and the BD Pathway 855
cell imaging platform was used for automated image acquisition.
In order to test the sensitivity and the capacity to detect EYFP and
ECFP separately using BD Pathway 855 bioimager, the co-
cultured cells were photographed for the two fluorochromes
sequentially and the images superimposed. In order to avoid
ECFP bleeding into the EYFP emission channel, a special filter set
was used that clearly separates the two fluorochromes. A third
fluorochrome, the far red/infrared fluorescent cell-permeant DNA
probe, DRAQ5, was employed to perform automated segmenta-
tion of cell nuclei. An image algorithm was applied to segment the
cell nucleus based on local thresholds. The ratios of the cyan and
yellow fluorescence signals were determined by dividing the
number of ECFP positive cells by the number of EYFP positive
cells in each well.
As a proof of principle, we sought to determine how a panel of
commercially available agents of known mechanism of action
would behave in the BaFiso screen. The test compounds included:
the DNA-damaging chemotherapeutic compound cisplatin; the
modulator of membrane lipid structure Minerval; the Akt inhibitor
10-(49-(N-diethylamino)butyl)-2-chlorophenoxazine (Akt Inhibitor
X); the protein tyrosine kinase inhibitor Genistein; the inhibitor of
nuclear export Leptomycin B; the broad protein kinase inhibitor
Staurosporine; the PDK1 inhibitor UCN-01; the Raf1 Kinase
Inhibitor; the PI3K inhibitor LY294002; the topoisomerase II
inhibitor Etoposide; and Lithium chloride, a GSK-3 inhibitor.
A robotic workstation was used to prepare mother plates
containing three different concentrations of these compounds. Co-
cultured BaFiso BYA/BCS cells were exposed to equal volumes of
the test compounds, resulting in a final concentration range
greater than two orders of magnitude around the IC50 value for
each compound. The final concentration of dimethyl sulfoxide was
kept at 1% after addition of the compounds. Each plate contained
several internal controls, including untreated wells and wells
treated with different concentrations of DMSO or ethanol alone.
The performance of the BaFiso system upon exposure to the panel
of test compounds was measured in terms of the ECFP/EYFP
ratio. The majority of the test compounds reduced the number of
DRAQ5 positive cells (Fig. 5A) without affecting the ratio of cyan
and yellow fluorescent signals (Fig. 5B), suggesting a non-selective
cytotoxic effect on both BaFiso cell lines independent of the gene
that has been engineered to sustain interleukin-3 independent
survival of the cells. In contrast exposure to Minerval or LiCl did
not affect the viability of the BaFiso cell lines (Fig. 5A) nor did it
alter the ratio of the fluorescent signals (Fig. 5B). Most importantly,
two compounds that are known to inhibit the kinase activity of
Akt, UCN-01 and Akt Inhibitor X, [16,17] selectively compro-
mised the viability of the yellow tagged BYA cells thereby
increasing the ratio of cyan to yellow fluorescent cells (Fig. 5B, C
and D). In contrast, the broad spectrum PI3K isoform inhibitor
LY294002 failed to affect the proportion of the fluorescent signals,
indicating that the myristoylated form of Akt bypasses the
requirement of PIP3-mediated membrane recruitment for its
activity. Taken together, these data demonstrate that we have
developed an image-based screening system that is capable of
identifying specific inhibitors of the Akt pathway.
Discussion
The most frequently used anti-cancer therapies were discovered
on the basis of their anti-proliferative activity in functional cell
assays but with no pre-existing knowledge of the mechanism of
action. As a result none of the current drugs directly targets the
molecular lesions responsible for malignant transformation and
they are not selective. Indeed this lack of selectivity between cancer
cells and normal cells is currently one of the main reasons for the
failure of conventional chemotherapy. In recent years, our
understanding of the genetics of human cancer has increased
rapidly, enabling more rational approaches to drug discovery for
anti-cancer therapies to be adopted. Accordingly, the present
study set out to develop a rational cell-based drug discovery
strategy, an approach that has historically been compromised by
the lack of appropriate control cells [18].
Figure 4. The analysis of Akt phosphorylation in BaFiso cell
lines. Immunoblot analysis of total lysates from the Ba/F3 derived cell
lines BY, BC, BYA and BCS. Cells were seeded, grown to 80% confluence
and starved for 12 h in IL-3 free medium (2IL-3) or maintained in
medium containing 3 ng/ml of the recombinant cytokine (+IL-3).
Relevant proteins are indicated by arrows in the blot from a
representative experiment.
doi:10.1371/journal.pone.0001823.g004
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With the objective of identifying lead compounds that
specifically kill cells with activated Akt signaling and that spare
control cells, we have combined the use of co-cultured isogenic cell
lines with fluorescent technology. We introduced a myristoylated
form of Akt which constitutively localizes to the plasma
membrane, bypassing the requirement for PIP3 in Akt activation.
This myr-Akt has been shown to constitutively inactivate pro-
apoptotic downstream targets [14]. In order to generate Ba/F3
cells that survive in the absence of IL-3 independent of activated
PI3K/Akt signaling, we transduced Ba/F3 cells with a retrovirus
encoding STAT5A1*6, an activated mutant of STAT5.
STAT5A1*6 has two amino acid substitutions and it is
constitutively phosphorylated, localized in the cell nucleus and
transcriptionally active in the absence of IL-3 [11]. In the BaFiso
system presented here, the protective potential of myr-Akt is
slightly greater than that provided by STAT5A1*6, which may be
explained by the greater expression of myr-Akt. The design of the
screen relies on the lack of relevant crosstalk between the pathways
engineered to support IL-3 independent survival. Previous work
has shown that the induced expression of bcl-xL and pim-1
promotes the IL-3-independent survival of Ba/F3 cells upon
activation of STAT5 [13]. In contrast, studies in multiple cell lines
suggest that Akt phosphorylates and inactivates proapoptotic
proteins such as GSK-3b, Foxo3a and Bad in response to IL-3
[8,19,20]. We confirmed that the activation of Stat5 signaling in
BCS cells did not increase Akt activity either in the presence or
absence of IL-3.
Another common source of interference to be mitigated in
multiplexed screening procedures is the bleed-through of fluores-
cence from one channel to the other. BaFiso allows simultaneous
viewing of three different fluorescent signals and sharp separation
of the emission signals from the cyan and yellow protein is
achieved using a special filter set. We implemented BaFiso as an
automated live-cell assay using a multidrop dispenser, a robotic
workstation and a robotic cell imaging platform. We assessed the
properties of this HTS co-culture assay using a panel of test
compounds of known activity. The cytotoxicity of the test
compounds was monitored by quantifying the DRAQ5 labelled
cells and all compounds tested except LiCl and Minerval reduced
the viability of Ba/F3 cells. The fact that only two compounds
known to selectively interfere with Akt signaling, Akt inhibitor X
and UCN-01, reduced the number of yellow tagged BYA cells
demonstrates the specificity of the BaFiso system. The Akt
inhibitor X is a N-substituted phenoxazine that inhibits the
activity of Akt even in the absence of its pleckstrin homology
domain and it has been suggested that it may bind in the ATP
binding site [17]. In contrast, UCN-01 has been reported to inhibit
several kinases including PDK1, a key regulator of Akt activity
[16]. Interestingly, staurosporine that differs from UCN-01 only
by the absence of a hydroxy group on the lactam ring failed to
change the ratio of the BaFiso cell lines. A specificity analysis
against a kinase panel revealed different patterns of inhibition for
UCN-01 with respect to staurosporine [16]. It remains to be
determined if these differences in specificity could account for the
different behaviour observed for these two compounds in the
BaFiso assay.
The BaFiso screening design presented here offers some major
advantages over traditional in vitro biochemical assays or more
classical cellular assays. Co-culture and simultaneous testing of the
paired isogenic cell lines in this assay provides an internal control
and eliminates errors resulting from separate assessments. BaFiso
is an image based high throughput assay that enables compound
that produce artefacts and cytotoxicity to be identified on a single
cell basis. Live cell imaging of the BaFiso cell lines permits the
Figure 5. Validation of BaFiso assay using a panel of test
compounds. (A) Analysis of the general toxicity of compound
treatment. The total cell numbers in each well were determined by
nuclear counterstain with the far-red fluorescent DNA probe DRAQ5.
The number of DRAQ5-stained nuclei was determined after exposure to
30 mM Cisplatin (Cis), 100 mM Minerval (Min), 500 nM Akt Inhibitor X
(AIX), 20 mM Genistein (Gen), 1 nM Leptomycin B (LMB), 20 nM
Staurosporine (Stau), 1 mM UCN-01, 20 nM Raf1 Kinase Inhibitor (RKI),
20 mM LY294002 (LY), 10 mM Etoposide (Eto) and 1 mM lithium chloride
(LiCl) for 12 hours and compared to vehicle treatment. (B) Equal
numbers of BCS and BYA cells were co-cultured in IL-3-free medium. We
exposed the paired BaFiso cell lines to 3 mM, 30 mM and 300 mM
Cisplatin (Cis), 25 mM, 100 mM, 200 mM Minerval (Min), 50 nM, 500 nM,
5 mM Akt Inhibitor X (AIX), 200 nM, 20 mM, 50 mM Genistein (Gen),
0.5 nM, 1 nM, 4 nM Leptomycin B (LMB), 2 nM, 20 nM, 10 mM
Staurosporine (Stau), 200 nM, 1 mM, 10 mM UCN-01; 5 nM, 20 nM,
200 nM Raf1 Kinase Inhibitor (RKI), 1 mM, 20 mM, 50 mM LY294002 (LY),
100 nM, 10 mM, 100 mM Etoposide (Eto) and 100 mM, 1 mM, 10 mM
lithium chloride (LiCl), and Dimethyl sulfoxide (DMSO) as a negative
control (striped bar). Three images specific for ECFP, EYFP or DRAQ5
from each well were acquired using BD Pathway Bioimager. The ECFP/
EYFP ratio was determined by dividing the number of ECFP positive
cells by the number of EYFP positive cells. Light, dark grey and black
bars represent low, medium and high concentrations of the corre-
sponding compounds, respectively. The data shown here represents
three independent experiments. The average Z’ value for BaFiso was
0.53. (C) Untreated, co-cultured BaFiso cells imaged before exposure to
Akt Inhibitor X and (D) 12 h after treatment with 5 mM AIX.
doi:10.1371/journal.pone.0001823.g005
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repeated monitoring of the same cells over the timecourse of an
experiment, leading to a more accurate assessment that minimizes
the variability in cell numbers between wells. Finally, the dual
fluorescence co-culture system used in BaFiso is adaptable to any
gene or pathway that can support IL-3 independent survival of
Ba/F3 cells.
Methods
Expression Vectors and Reagents
The enhanced fluorescent protein vectors (pECFP-C1 and
pEYFP-C1) were purchased from Clontech. The cDNAs encoding
ECFP and EYFP were subcloned into the SnaBI sites of the pBABE-
puro retroviral vector. The myr-Akt was kindly provided by Dr.
Philip Tsichlis and we PCR amplified myr-Akt-HA using forward
59–CGCGGATCCATGGGGAGCAGCAAGAGCAAGC–39 and
reverse 59–ACGCGTCGACTCATCTAGAAGCGTAATCTG-
GAACC–39 primers, before subcloning the BamHI and SalI
digested PCR product into the corresponding restriction site of the
retroviral vector pWZL-Blast. The Stat5A1*6-Flag construct was a
kind gift from T. Nosaka (University of Tokyo). The nature of all
constructs was confirmed by DNA sequencing.
All chemicals were purchased from commercial sources except
UCN-01 which was kindly provided by NCI, Cisplatin which was
provided by C. Navarro (Universidad Auto´noma de Madrid,
Spain), and Minerval which was generously provided by P. Escriba
(University of the Balearic Islands, Palma de Mallorca, Spain).
The Akt Inhibitor X, LY294002 and Raf1 Kinase Inhibitor were
purchased from Calbiochem (San Diego, CA), Leptomycin B and
Genistein were purchased from LC Laboratories (Woburn, MA,
USA), Lithium chloride (LiCl), Etoposide and Staurosporine ware
all purchased from Sigma-Aldrich (St. Louis, USA).
Cell Culture
Murine pro-B Ba/F3 cells were obtained from the American
Type Culture Collection (ATCC) and maintained in RPMI 1640
containing: 10% fetal calf serum; 2 mM L-glutamine; 50 mM 2-
mercaptoethanol (Sigma); antibiotics and antimycotics (Gibco);
and 3 ng/ml of recombinant murine IL-3 (R&D Systems,
Minneapolis, MN, USA). LinXE ecotropic retrovirus producing
cells [21] were grown in Dulbecco’s modified Eagle’s medium with
glutamax supplemented with 10% fetal bovine serum (FBS),
penicillin, streptomycin and fungizone (Gibco). Cell cultures were
maintained in a humified incubator at 37uC with 5% CO2. To
remove IL-3, the cells were washed twice in PBS at room
temperature. Retroviral constructs were introduced into packaging
cells by standard calcium phosphate transfection and retroviral-
mediated gene transfer was performed as described previously
[22]. After infection of Ba/F3 cells with retroviral supernatants
containing either EYFP or ECFP, stable cell lines were selected in
medium containing 2 mg/ml of puromycin for one week. In order
to establish Ba/F3 cell lines homogeneously expressing EYFP or
ECFP, we performed clonal propagation in Clona-cell TCS semi-
solid culture medium (Stem Cell Technologies, Vancouver,
Canada) containing 2 mg/ml puromycin according to the
manufacturer’s protocol. Ba/F3 cell clones stably expressing
EYFP (BY cells) or ECFP (BC cells) were used as parental cells
for the secondary stable infection with retroviral supernatants
containing either myr-Akt or Stat5A1*6-Flag, respectively. Stable
Ba/F3 cells co-expressing EYFP and myr-Akt (BYA cells) were
selected with 0.8 mg/ml Neomycin and 1 mg/ml puromycin for
2 weeks. Stable Ba/F3 cells co-expressing ECFP and Stat5A1*6-
Flag (BCS cells) were selected with 15 mg/ml Blasticidine and
1 mg/ml puromycin for 2 weeks. The generation of cell clones was
performed as described above. Fluorescence-activated cell sorting
(FACS) of EYFP or ECFP expressing cells was performed on a
FACSAria (BD Biosciences, San Jose, CA, USA).
Western Blot Analysis
Cells incubated under different conditions were washed twice
with TBS prior to lysis in buffer containing: 50 mM Tris HCl,
150 mM NaCl, 1% NP-40, 2 mM Na3VO4, 100 mM NaF,
20 mM Na4P2O7, and protease inhibitor cocktail (Roche Molec-
ular Biochemicals, Indianapolis, IN). Proteins were resolved on
10% SDS-PAGE, and transferred to PVDF membranes (Im-
mobilon-P, Millipore). The membranes were incubated with the
first antibody overnight at 4uC, washed and incubated with anti-
mouse (1:10000) or anti-rabbit (1:5000) horseradish peroxidase
conjugated antibodies. Immunoreactive proteins were visualized
using the enhanced chemiluminescence (ECL) Western blotting
detection system (Amersham Pharmacia Biotech) and Kodak-X-
Omat LS film (Kodak). Antibodies against phospho-AKT (Ser473)
and AKT were purchased from Cell Signaling (Beverly, MA),
those against STAT-5 from (R&D Systems, Minneapolis, MN,
USA), and the antibodies against a-tubulin and Flag were obtained
from Sigma (St Louis, MO).
Survival assay
Each cell line was individually seeded at 104 cells per well in a
96 well plate, in the presence or absence of IL-3. AlamarBlueTM
(Serotec, Oxford, UK) was added to the culture medium at a final
concentration of 10% (v-v) and after 24 hours, absorbance was
measured at the two different wavelengths of maximal absorbance
of the reduced and oxidized forms of AlamarBlueTM, 570 and
600 nm using Victor 1420 Multilabel Counter (Perkin-Elmer,
Wellesley, USA). The percentage cell survival was calculated
according to the manufacturers’ instructions. Time course
experiments of cell viability post IL-3 withdrawal were performed
using trypan blue exclusion.
BaFiso assay
Equal numbers of parental BC/BY cells or activated test cells
BCS/BYA were mixed in culture medium deprived of IL-3 and
seeded in 96-well black clear bottom microplates coated with Poly-
D-Lysine (Becton Dickinson Biosciences, San Jose, California,
USA) at a density of 20,000 cells per well using Titan Multidrop
384 automatic dispenser (Titertek Instruments, Inc., Huntsville,
AL). The final volume of the cell suspension was 200 ml in each
well. After incubation at 37uC with 5% CO2 for 1 hour the far-red
fluorescent cell-permeable DNA probe, DRAQ5TM (Biostatus Ltd,
Leicestershire, UK) was added at a final concentration of 5 mM to
all wells 15 minutes prior to obtaining the first images. Then, 2 ml
of each test compound or vehicle was transferred from the mother
plates to the assay plates using a robotic workstation (BiomekR FX
Beckman). Cells were incubated in the presence of the test
compounds for 12 hours.
Image acquisition and processing
Assay plates were read on the BD PathwayTM 855 Bioimager
(Becton Dickinson Biosciences, San Jose, California, USA)
equipped with a 430/25 nm/470/30 nm ECFP excitation/
emission filter, 500/20 nm/535/30 nm EYFP excitation/emis-
sion filter and 635/20 nm/695/55 nm DRAQ5 excitation/
emission filter. Images for each well were acquired in the three
different channels for ECFP, EYFP and DRAQ5 using a 206dry
objective. The plates were exposed for 0.55 ms (Gain 14) to
acquire ECFP images, 0.68 ms (Gain 32) for EYFP images and
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0.47 ms (Gain 5) to acquire DRAQ5 images. The far red
fluorescence intensity of DRAQ5 was used to perform automated
segmentation of the cell nuclei and in turn to quantify the total cell
number.
Data analysis
The data output of the BD Pathway Bioimager is as standard
text files. These files contained the raw fluorescence data for each
cells population. Data were imported into the data analysis
software, BD Image Data Explorer, and the ratios of the ECFP
positive cells to EYFP positive cells were determined by dividing
the number of cyan fluorescence-emitting single cells by the
number of yellow fluorescence-emitting single cells in each well.
This procedure was repeated for each well. By measuring changes
in the ratio between the cyan and yellow signal, the possible
pathway-specific cytotoxicity of each compound could be
determined. In order to estimate the quality of the HCS assay,
the Z’ factor was calculated by the equation: Z’ = 1 – [(36std. dev.
of positive controls)+(36std. dev. of negative controls)/(mean of
positive controls) - (mean of negative controls)] as described
previously [23].
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